NANOLEK and BIOKOM: vital and important medicines

Companies NANOLEK and BIOKOM signed with the Ministry of Industry and Trade of the Russian Federation State contracts for the development of four vital and essential drugs are not produced by domestic manufacturers and unprotected by patents of foreign companies on the territory of the Russian Federation. Company will develop, organize the production and recording of anticancer drugs "Lomustine" and "Procarbazine",
for the treatment of leukemia "Tretinoin", as well as the anti-malaria drug "Hydroxychloroquine". R & D will be carried out in the framework of the federal target program "Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and beyond."

The total amount of state contracts is 105 million rubles, of which 47 million rubles — government funding. 

The company will perform BIOKOM performer and NANOLEK — co-development, production and registration of anticancer drugs procarbazine, lomustine, and, for the treatment of leukemia tretinoin, as well as the anti-malarial drug hydroxychloroquine.

As part of these commitments NANOLEK will produce work to develop and register drugs. The production of new drugs in pill form will be adjusted at production sites and BIOKOM NANOLEK. In particular the production of medicines will be adjusted at NANOLEK biopharmaceutical company in the Kirov region, which will be launched in 2014. Under the terms of the contracts by the end of 2014 all work must be completed.

Like this post? Please share to your friends: